Notably, BTYNB, an inhibitor of IGF2BP1, has been shown to exert antiproliferative effects in IGF2BP1-expressing ovarian cancer and melanoma cells, while exhibiting no effects in IGF2BP1-negative cells [90]. Here, IGF2BP1 is linked to ovarian carcinoma.